CVS Health Corp.
Can Aetna's margin recovery and a stabilized retail pharmacy outrun shrinking PBM membership and profit while Medicare rates and state laws constrain pricing?
Last 4 earnings calls · through Q2 FY2026
Bull case
Aetna margin recovery
The bull case rests on Aetna, where two years of repricing and disciplined bidding have turned a loss-making insurer into the fastest-improving part of the company.
Retail pharmacy turnaround
Retail pharmacy has gone from a business expected to shrink to one that grows earnings, helped by cost-based reimbursement and share gains from failed competitors.
Repeated guidance raises
Management has raised its full-year earnings outlook at each of the last several reports and argues the growth it promises for next year is credible rather than aspirational.
Cash flow and leverage
Rising cash generation and falling leverage give the company room to keep investing in technology and to restore buybacks once the balance sheet allows.
Bear case
PBM client renewals
The bear case says the pharmacy benefit business is losing clients and repricing contracts at lower economics, so its profit shrinks while the rest of the company improves.
Medicare rate setting
Government rate notices have lagged medical cost trends for years, so Aetna's recovery depends on repricing and benefit cuts that may be hard to repeat each year.
State pharmacy laws
States are passing laws that restrict how the pharmacy and PBM businesses contract with each other, and CVS is fighting them in court rather than pricing around them.
Thin operating margins
Operating margins are thin relative to the revenue base, so a small miss on medical costs or drug purchasing swings a large amount of reported profit.
Bull and bear points
Growth & Execution
In short: Aetna margin recovery and pharmacy stabilization lift earnings, while PBM client renewals shrink membership.
Aetna recovery supports another guidance raise
Aetna's margin recovery drove management to raise full-year 2026 adjusted EPS guidance to $7.90 to $8.10, about 8% above the prior range.
Q2 FY2026 callPharmacy outlook shifts from decline to growth
A year ago management guided retail pharmacy earnings to a 5% annual decline; it now says earnings will be at least flat and is posting mid-single-digit growth.
Tone shiftQ3 FY2025 → Q4 FY2025
Caremark membership set to shrink in 2027
A year ago the pharmacy services segment was guided to low single-digit profit growth; management now warns of member losses in 2027 as it reunderwrites client contracts.
Tone shiftQ3 FY2025 → Q2 FY2026Client price concessions squeeze pharmacy services profit
Pharmacy services revenue is growing at a double-digit rate while segment profit fell in the first quarter of 2026, because price concessions to PBM clients offset purchasing gains.
Q1 FY2026 call
Profitability & Financial Strength
In short: Cash generation has improved sharply and leverage is falling, but operating margins remain thin.
Free cash flow nearly tripled year over year
Free cash flow of $11.8 billion over the last twelve months is up from $4.8 billion a year earlier, so the dividend and debt paydown come from operations rather than borrowing.
Filed financialsLeverage falls as earnings and cash grow
The leverage ratio fell to about 3.5 times from roughly 4 times at the end of 2025, and management says share repurchases become an option as the balance sheet strengthens.
Q2 FY2026 call
Thin operating margin leaves little room for error
A 4.4% operating margin leaves little cushion: a one-point change in medical cost trend or drug purchasing is worth billions of dollars of reported profit.
Filed financialsGoodwill write-downs show capital sunk in clinics
A large goodwill charge on Health Care Delivery followed the decision to slow Oak Street clinic openings, and further write-downs are possible while that business is rebuilt.
Q3 FY2025 call
Market Position
In short: CVS has unmatched US pharmacy and PBM scale, but state pharmacy laws and Medicare rates constrain pricing.
Medicare Advantage star ratings lead the industry
Most Aetna Medicare Advantage members are in plans rated four stars or higher, which supports enrollment and quality payments even as cut points get harder.
Q3 FY2025 callBiosimilar formulary actions cut client drug costs
Caremark moved most Humira patients to a lower-price biosimilar and plans the same for Stelara, which keeps clients reliant on its purchasing scale and specialty pharmacy.
Q4 FY2025 call
State PBM laws threaten pharmacy integration
Tennessee and Arkansas passed laws CVS says raise costs and restrict how its pharmacies and PBM contract; the company is litigating, and the Tennessee law starts in mid-2028.
Q2 FY2026 call340B manufacturer limits pressure PBM profit
Drugmakers are restricting how covered entities use contract pharmacies, which management says hurt Caremark profit in the second quarter and will be a headwind into 2027.
Q2 FY2026 call